Cramer Weighs In On Cytokinetics, LegalZoom And Matterport
On CNBC's "Mad Money Lightning Round," Jim Cramer said Cytokinetics, Inc. (NASDAQ: CYTK) is a very good spec. Big pharma needs these companies, he added.
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
LegalZoom.com Q2 EPS $0.03 Beats $0.02 Estimate, Sales $150.40M Beat $139.38 Estimate
LegalZoom.com (NASDAQ:LZ) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 50 percent. The company reported quarterly sales of $150.40 million which beat the analyst
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Citigroup Initiates Coverage On LegalZoom.com with Neutral Rating, Announces Price Target of $40
Citigroup analyst Jason Bazinet initiates coverage on LegalZoom.com (NASDAQ:LZ) with a Neutral rating and announces Price Target of $40.
Morgan Stanley Initiates Coverage On LegalZoom.com with Equal-Weight Rating, Announces Price Target of $44
Morgan Stanley initiates coverage on LegalZoom.com (NASDAQ:LZ) with a Equal-Weight rating and announces Price Target of $44.
William Blair Initiates Coverage On LegalZoom.com with Outperform Rating
William Blair analyst Matthew Pfau initiates coverage on LegalZoom.com (NASDAQ:LZ) with a Outperform rating.
Raymond James Initiates Coverage On LegalZoom.com with Market Perform Rating
Raymond James analyst Aaron Kessler initiates coverage on LegalZoom.com (NASDAQ:LZ) with a Market Perform rating.